Pregled bibliografske jedinice broj: 400482
ORAMA : a study to investigate EBPG impact on renal anaemia – design and baseline data
ORAMA : a study to investigate EBPG impact on renal anaemia – design and baseline data // JN. Journal of nephrology, 21 (2008), 4; 592-602 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 400482 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
ORAMA : a study to investigate EBPG impact on renal anaemia – design and baseline data
Autori
Locatelli, F. ; Čović, Adrian ; Macdougall, I.C. ; Wiecek, A.
Izvornik
JN. Journal of nephrology (1121-8428) 21
(2008), 4;
592-602
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
anaemia management guidelines; Chronic kidney disease; Clinical decision support system; Erythropoiesis-stimulating agents; European best practice guidelines; ORAMA; Renal anaemia; Recombinant-human-erythropoietin; Chronic kidney-disease; Hemodialysis-patients; Practice guidelines; Dialysis outcomes; Practice patterns; Management; Mortality; Quality; Performance
Sažetak
Background: It is of paramount importance not only to publish anaemia management guidelines for chronic kidney disease (CKD) but also to verify their implementation in clinical practice. The Optimal Renal Anaemia Management Assessment (ORAMA) is the first European study investigating the impact of adherence to the 2004 revised European Best Practice Guidelines (EBPG) and its impact on patient outcomes. Participating centres were randomised into 2 groups: group A with, and group B without, access to an EBPG-based computerised clinical decision support (CDS) system after baseline. Patients with stage 2-5 CKD either anaemic (haemoglobin [Hb] <11 g/dL) or treated with erythropoiesis-stimulating agents (ESAs) and/or iron supplementation were enrolled. Primary end points are based on achievement of anaemia-related guideline targets. Here, baseline data are reported descriptively. Fifty-three centres in 8 countries included 739 patients, 81% of whom have received dialysis. Mean baseline Hb was 11.2 g/dL, and 52% of all patients met the EBPG target of >11 g/dL Hb at baseline. However, only 37% of patients had their Hb values >11 g/dL throughout a 3-month prestudy period. Serum ferritin and transferrin saturation were above the guideline target in circa 80% of patients. The vast majority of patients (96%) received ESA therapy at baseline. In line with findings from previous studies ORAMA baseline data show that achievement of EBPG is suboptimal across European countries. Final results promise an insight into the impact of guideline-based CDS tools on clinical practice and target attainment.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
219-0000000-3362 - Genski polimorfizam i funkcija bubrežnog presatka (Barbić, Jerko, MZOS ) ( CroRIS)
Ustanove:
Opća bolnica "Dr. Josip Benčević",
Medicinski fakultet, Osijek
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE